DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Kelly Shi - 3 Shi - 2 Jonathan Raa - 1 Johnson - 1 Myers's - 1 Bristol Myers - 1 Jefferies - 1 Carvykti - 1
Top related locs:
Beijing China Bristol U.S EU Japan Mount Sinai New York City
Top related orgs:
Getty - 2 Nurphoto - 1 Bristol Myers Squibb - 1 Johnson - 1 Food and Drug Administration - 1 FDA - 1 Legend Biotech - 1 Bristol - 1

Search resuls for: "Kelly Shi"


3 mentions found


☆ Healthy Returns: J&J cell therapy gains new edge over Bristol Myers rival
  + stars: | 2024-04-09 | by ( Annika Kim Constantino Ashley Capoot | Annika Kim Constantino | Ashley Capoot | ) www.cnbc.com   time to read: +4 min
But J&J's drug is walking away with a notable edge over its rival. They add more options to a growing arsenal of treatments that have helped improve outcomes for people with multiple myeloma. But the new approvals also give J&J's therapy, which was developed with Legend Biotech, a clear advantage over Bristol Myers's drug. J&J's drug has gradually gained ground over Abecma in the CAR-T market for multiple myeloma, even though it first entered the market a year later. With the new approval on Friday, Jefferies' Shi expects J&J's drug to win the majority of that market share.
Persons: Jonathan Raa, Johnson, Myers's, Bristol Myers, Jefferies, Kelly Shi, Shi, Carvykti, Cantor Fitzgerald, Rick Bienkowski, Kelsey Goodwin, Annika, annikakim.constantino@nbcuni.com Organizations: Nurphoto, Bristol Myers Squibb, Johnson, Food and Drug Administration, FDA, Legend Biotech, Bristol, New York Stock Exchange, NYSE, Reuters, Mount Sinai Hospital, Getty Locations: Bristol, U.S, EU, Japan, Mount Sinai, New York City
☆ This biotech stock is a cancer-fighting 'powerhouse' with nearly 50% upside, says Jefferies
  + stars: | 2023-08-17 | by ( Pia Singh | ) www.cnbc.com   time to read: +3 min
Investors should keep an eye on biotech company BeiGene as it scales up its global revenue streams, according to Jefferies. Analyst Kelly Shi initiated coverage of the stock with a buy rating and assigned a price target of $287, suggesting shares stand to gain 49.2% in the next 12 months. The stock has lost 12% so far this year but has had a more uplifting quarter with gains of about 8%. According to the analyst, BeiGene's product pipeline could expand beyond oncology, as it currently includes early autoimmune candidates. BeiGene's tislelizumab drug is another major growth driver for the company, Shi said, highlighting the drug's position as China's top-selling PD-1 drug with about 40% market share.
Persons: Kelly Shi, Shi, BeiGene, BGNE, Amgen, — CNBC's Michael Bloom Organizations: Jefferies, pharma, Novartis Locations: Cambridge , Massachusetts, Beijing, China, BeiGene
☆ What one key business indicator is saying about China's consumer recovery
  + stars: | 2023-06-12 | by ( Evelyn Cheng | ) www.cnbc.com   time to read: +4 min
"For 618, generally of course brands will be trying, but compared to before it's a bit more tired," said Ashley Dudarenok, founder of ChoZan, a China marketing consultancy. In the first quarter, the median disposable income of urban residents in China was officially 12,175 Chinese yuan ($1,739), up 3.9% from a year ago. A focus on affordabilitySluggish economic growth and uncertainty about future income have weighed on Chinese consumer spending since the Covid-19 pandemic. watch nowBrands are keen to spend more on ByteDance's Douyin, likely taking away from ad spending on Alibaba's Taobao and Tmall e-commerce platforms, Oliver Wyman's Xie said. And for brands spending on Douyin, he said the return on investment per ad dollar was getting lower.
Persons: Jade Gao, Ashley Dudarenok, Dudarenok, let's, Microsoft's Bing, Dave Xie, Oliver Wyman, Douyin, Oliver Wyman's Xie, ByteDance isn't, doesn't, Pinduoduo, Sun Hao, Sun, didn't, Trip.com, Kelly Shi Organizations: Afp, Getty, Baidu, Retail, Brands, Growth, Nestle, Netflix Locations: Beijing, BEIJING, China
0 next >>
Total: 3